Fulminant type 1 diabetes mellitus associated with pembrolizumab

Endocrinol Diabetes Nutr. 2017 May;64(5):272-273. doi: 10.1016/j.endinu.2017.01.005. Epub 2017 Mar 15.

[Article in English, Spanish]

Authors

Chadia Mizab Mellah¹, Marta Sánchez Pérez¹, María Dolores Santos Rey¹, Marta Hernández García²

Affiliations

¹ Servei d'Endocrinología y Nutrició, Hospital Universitari Arnau de Vilanova, Lleida, España.
² Servei d'Endocrinología y Nutrició, Hospital Universitari Arnau de Vilanova, Lleida, España; Institut de Recerca Biomèdica de Lleida, IRB Lleida, Lleida, España. Electronic address: martahernandezg@gmail.com.

PMID: 29056250
DOI: 10.1016/j.endinu.2017.01.005

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / diagnosis
Diabetes Mellitus, Type 1 / immunology
Humans
Male
Melanoma / drug therapy
Melanoma / secondary
Middle Aged
Molecular Targeted Therapy / adverse effects

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab